Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

The Vasoactive Peptide Maxadilan from Sand Fly Saliva Inhibits TNF-α and Induces IL-6 by Mouse Macrophages Through Interaction with the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Receptor

Milena B. P. Soares, Richard G. Titus, Charles B. Shoemaker, John R. David and Marcelo Bozza
J Immunol February 15, 1998, 160 (4) 1811-1816;
Milena B. P. Soares
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard G. Titus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles B. Shoemaker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. David
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcelo Bozza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Maxadilan modulates TNF-α and IL-6 release by macrophages stimulated with LPS. BALB/c macrophages were preincubated for 2 h with different doses of maxadilan. An amount equal to 500ng/ml of LPS was then added to the macrophage monolayers and, 2 h (A) or 4 h (B) later, cell-free supernatants were collected. TNF-α and IL-6 contents were determined by ELISA. Values are shown as percent of LPS control from three independent experiments, expressed as mean ± SEM. * p < 0.05 compared with LPS alone. Levels of TNF-α in LPS control cultures varied from 100 pg/ml to 3 ng/ml, and of IL-6, from 1 to 6 ng/ml.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Maxadilan induces IL-6 release by normal macrophages. BALB/c macrophages were incubated for 6 h with the indicated doses of recombinant maxadilan. Supernatants were collected and tested for IL-6 by ELISA. Data represent the mean ± SEM of three separate experiments.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    The inhibition of TNF-α by maxadilan on LPS-stimulated macrophages is blocked by indomethacin but not by anti IL-10. Macrophages were plated as described in Materials and Methods. After 2 h preincubation in the presence or in the absence of anti-IL-10 (5 μg/ml), indomethacin (1 μg/ml), and maxadilan (10 ng/ml), LPS (500 ng/ml) was added for an additional 4 h. Supernatants were collected and tested for TNF-α by ELISA. Results shown are from one representative of four independent experiments performed. Values are expressed as mean ± SEM of four determinations.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Maxadilan increases PGE2 from macrophages stimulated by LPS. BALB/c macrophages were preincubated for 2 h with different doses of maxadilan. An amount equal to 500 ng/ml of LPS was then added to the macrophage monolayers, and, 2 h later, the cell-free supernatants were collected and tested for the presence of PGE2 by enzyme immunoassay. Values are shown as percent of LPS control from four independent experiments, expressed as mean ± SEM. * p < 0.05 compared with LPS alone. Levels of PGE2 in LPS control cultures varied from 100 pg/ml to 1.5 ng/ml.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    PACAP 6–38 blocks the effects of maxadilan on macrophages. BALB/c macrophages were preincubated for 2 h with maxadilan (10 ng/ml) in the presence or absence of PACAP 6–38 (1 μg/ml). LPS (500 ng/ml) was then added and the supernatants were collected after 2 or 4 h for TNF-α (A) and IL-6 (B), respectively, and tested by ELISA. Results shown are from one representative of five independent experiments performed. Values represent mean ± SD of four determinations.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Maxadilan dramatically enhances the level of intracellular cAMP in macrophages. A, Time course of cAMP accumulation. BALB/c macrophages were incubated with 10 ng/ml of maxadilan for different times, and the levels of intracellular cAMP were determined (techniques in Material and Methods). B, Dose response of cAMP accumulation. BALB/c macrophages were incubated with different doses of maxadilan for 15 min, and the levels of intracellular cAMP were determined. The figure is representative of three independent experiments.

Tables

  • Figures
    • View popup
    Table I.

    PACAP 38 modulates cytokine release by macrophagesa

    Experiment1234
    TNF-α (ng/ml)
    Medium0000
    LPS0.340.161.130.55
    PACAP0000
    PACAP + LPS0.130.040.700.20
    IL-6 (ng/ml)
    Medium0000
    LPS1.995.361.612.96
    PACAP0.551.080.781.55
    PACAP + LPS3.056.381.923.49
    • a BALB/c macrophages were preincubated for 2 h in the presence or absence of 10 ng/ml of PACAP 38. LPS (500 ng/ml) was added, and supernatants were collected after 4 h for TNF-α and IL-6 and tested by ELISA. Using the Mann-Whitney test, the decrease in TNF-α and increase in IL-6 when PACAP is preincubated with macrophages before adding LPS is significant, p < 0.05.

PreviousNext
Back to top

In this issue

The Journal of Immunology
Vol. 160, Issue 4
15 Feb 1998
  • Table of Contents
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Vasoactive Peptide Maxadilan from Sand Fly Saliva Inhibits TNF-α and Induces IL-6 by Mouse Macrophages Through Interaction with the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Receptor
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Vasoactive Peptide Maxadilan from Sand Fly Saliva Inhibits TNF-α and Induces IL-6 by Mouse Macrophages Through Interaction with the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Receptor
Milena B. P. Soares, Richard G. Titus, Charles B. Shoemaker, John R. David, Marcelo Bozza
The Journal of Immunology February 15, 1998, 160 (4) 1811-1816;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Vasoactive Peptide Maxadilan from Sand Fly Saliva Inhibits TNF-α and Induces IL-6 by Mouse Macrophages Through Interaction with the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Receptor
Milena B. P. Soares, Richard G. Titus, Charles B. Shoemaker, John R. David, Marcelo Bozza
The Journal of Immunology February 15, 1998, 160 (4) 1811-1816;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Early Self-Regulatory Mechanisms Control the Magnitude of CD8+ T Cell Responses Against Liver Stages of Murine Malaria
  • Sublethal Hyperoxia Impairs Pulmonary Innate Immunity
  • Dependence of IL-4, IL-13, and Nematode-Induced Alterations in Murine Small Intestinal Smooth Muscle Contractility on Stat6 and Enteric Nerves
Show more HOST DEFENSE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606